N/A
Completed N=563
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
Source: ClinicalTrials.gov NCT01664494 ↗Enrolled (actual)
563
Serious AEs
6.0%
Results posted
May 2016
Primary outcomePrimary: Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment — 220; 176; 89; 78 Participants
Summary
This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment |
220; 176; 89; 78 | — |
| SECONDARY Median Dose of Capecitabine |
3500; 3000 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer or breast cancer who are candidates for receiving Xeloda according to product label
Exclusion Criteria
- Contraindications according to label and off-label use
Data sourced from ClinicalTrials.gov (NCT01664494). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.